Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
US Army
Baxter
Healthtrust
Boehringer Ingelheim
Cipla
Fish and Richardson
Julphar

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TENOFOVIR DISOPROXIL FUMARATE

« Back to Dashboard

Clinical Trials for Tenofovir Disoproxil Fumarate

Trial ID Title Status Sponsor Phase Summary
NCT00002450 Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients Completed Gilead Sciences Phase 3 The purpose of this study is to see if giving tenofovir DF plus a combination of other anti-HIV drugs is safe and effective.
NCT00002453 A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection Completed Gilead Sciences N/A This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.
NCT00007436 The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients Unknown status Gilead Sciences Phase 3 The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated in other tenofovir DF studies (GS-98-902 or GS-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir DF treatment.
NCT00011089 Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations Unknown status Gilead Sciences N/A The purpose of this study is to make tenofovir disoproxil fumarate (DF) available to HIV-infected patients who have failed other anti-HIV drug combinations, who have few treatment choices available, and whose disease may get worse. This study will allow patients to obtain tenofovir DF before it is approved for marketing.
NCT00013520 Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs). The current rule for starting treatment of HIV infection is to combine members from different classes of anti-HIV drugs, such as 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either a PI or a nonnucleoside reverse transcriptase inhibitor (NNRTI). However, these combinations can be complicated and difficult to take, can cause a number of side effects, and may become ineffective. Combinations that are simpler, better tolerated, and more effective are needed. Because PIs can cause long-term side effects and because HIV can become resistant to many of them at the same time, anti-HIV combination treatments that do not use PIs are being tested.
NCT00016588 Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs Completed Gilead Sciences N/A The purpose of this study is to look at the effectiveness of tenofovir disoproxil fumarate (TDF) in HIV-infected patients who have never taken anti-HIV drugs.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Tenofovir Disoproxil Fumarate

Condition Name

Condition Name for Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 97
HIV 38
Chronic Hepatitis B 35
HIV-1 Infection 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 132
Hepatitis 80
Hepatitis B 77
Hepatitis A 62
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tenofovir Disoproxil Fumarate

Trials by Country

Trials by Country for Tenofovir Disoproxil Fumarate
Location Trials
China 115
Canada 108
United Kingdom 55
Australia 52
Germany 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tenofovir Disoproxil Fumarate
Location Trials
California 94
New York 77
Florida 66
Texas 59
North Carolina 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tenofovir Disoproxil Fumarate

Clinical Trial Phase

Clinical Trial Phase for Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Phase 4 71
Phase 3 79
Phase 2/Phase 3 8
[disabled in preview] 87
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Completed 143
Active, not recruiting 46
Recruiting 45
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tenofovir Disoproxil Fumarate

Sponsor Name

Sponsor Name for Tenofovir Disoproxil Fumarate
Sponsor Trials
Gilead Sciences 104
National Institute of Allergy and Infectious Diseases (NIAID) 57
Merck Sharp & Dohme Corp. 15
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tenofovir Disoproxil Fumarate
Sponsor Trials
Other 225
Industry 189
NIH 74
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Fish and Richardson
UBS
Argus Health
Teva
Covington
Daiichi Sankyo
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.